F Schmitt

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

S Michiels, B Asselain, J Bogaerts, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Digital image documentation for quality assessment.

F Schmitt, D Cruz, C Valentí, 2001, Archives of pathology & laboratory medicine.

GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression.

F. Schmitt, A. Albergaria, F. Baltazar, 2011, Histology and histopathology.